论文部分内容阅读
目的研究替吉奥单药治疗晚期初治胃癌患者的临床疗效。方法从2013年1月至2014年7月确诊为胃癌晚期且符合入选标准的患者中选取50例,随机分为对照组和实验组。实验组给予替吉奥单药胶囊口服治疗,对照用FOLFOX4方案进行治疗,2个疗程后观察疗效和不良反应。结果实验组有效率为40%,明显高于对照组的16%,差异有统计学意义(u=-2.5783,P=0.0099),实验组不良反应发生率明显低于对照组,差异有统计学意义(P<0.05)。结论替吉奥单药治疗晚期初治胃癌患者的临床疗效较为显著,不良作用反应轻微,患者能够耐受。
Objective To study the clinical efficacy of TEGO monotherapy in the treatment of advanced gastric cancer patients with advanced disease. Methods From January 2013 to July 2014, 50 patients who were diagnosed as advanced gastric cancer and met the inclusion criteria were randomly divided into control group and experimental group. The experimental group was treated with TIGO single capsule orally, the control was treated with FOLFOX4 regimen, and the curative effect and adverse reactions were observed after 2 courses. Results The effective rate of the experimental group was 40%, significantly higher than that of the control group (16%), the difference was statistically significant (u = -2.5783, P = 0.0099). The incidence of adverse reactions in the experimental group was significantly lower than that in the control group Significance (P <0.05). Conclusion The efficacy of TEGO monotherapy in the treatment of advanced gastric cancer patients with advanced stage is significant, and the adverse reactions are mild and the patients are able to tolerate.